The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Agile Therapeutics Past Earnings Performance
Past criteria checks 0/6
Agile Therapeutics has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 66.5% per year.
How Agile Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:AGRX Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 24
22
-16
25
2
31 Mar 24
21
-8
27
2
31 Dec 23
20
-14
28
2
30 Sep 23
20
-14
32
3
30 Jun 23
16
-19
33
3
31 Mar 23
13
-20
35
3
31 Dec 22
11
-25
42
3
30 Sep 22
8
-41
50
5
30 Jun 22
7
-52
54
5
31 Mar 22
6
-64
60
5
31 Dec 21
4
-71
58
6
30 Sep 21
3
-69
56
8
30 Jun 21
2
-68
54
10
31 Mar 21
1
-61
45
12
31 Dec 20
1
-52
36
14
30 Sep 20
0
-40
25
13
30 Jun 20
0
-29
16
12
31 Mar 20
0
-22
12
10
31 Dec 19
0
-19
9
10
30 Sep 19
0
-16
7
9
30 Jun 19
0
-16
7
8
31 Mar 19
0
-18
7
9
31 Dec 18
0
-20
9
10
30 Sep 18
0
-22
10
11
30 Jun 18
0
-26
12
12
31 Mar 18
0
-28
13
14
31 Dec 17
0
-28
12
14
30 Sep 17
0
-27
11
17
30 Jun 17
0
-28
10
19
31 Mar 17
0
-29
9
21
31 Dec 16
0
-29
9
21
30 Sep 16
0
-27
9
22
30 Jun 16
0
-29
8
25
31 Mar 16
0
-29
8
25
31 Dec 15
0
-30
7
26
30 Sep 15
0
-33
7
24
30 Jun 15
0
-30
6
21
31 Mar 15
0
-25
6
17
31 Dec 14
0
-16
5
13
30 Sep 14
0
-12
4
10
30 Jun 14
0
-9
4
7
31 Mar 14
0
-10
3
7
Quality Earnings: AGRX is currently unprofitable.
Growing Profit Margin: AGRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGRX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare AGRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: AGRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/08/26 16:15
End of Day Share Price
2024/08/26 00:00
Earnings
2024/06/30
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agile Therapeutics, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.